Finoriq insights
Moderna, Inc. (MRNA) SEC Filings & Filing Highlights
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States. Review MRNA SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
- Company
- Moderna, Inc. (MRNA)
- Ticker
- MRNA
- Market Cap
- $55B
- Latest Price
- $137.65
- Industry
- Biotech & Pharma
Moderna, Inc. (MRNA) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Moderna, Inc. (MRNA).
| Event | Form | Date |
|---|---|---|
| On May 6, 2026, the Company held its previously announced 2026 Annual Meeting of Stockholders,...On May 6, 2026, the Company held its previously announced 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was... | 8-K5.07 | 2026-05-11 |
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K5.03 | 2026-05-11 |
| Moderna Reports First Quarter 2026 Financial Results and Provides Business UpdatesModerna Reports First Quarter 2026 Financial Results and Provides Business Updates | 8-K2.02 | 2026-05-01 |
| Moderna, Inc.: Material agreementOn March 3, 2026 (the “Effective Date”), Moderna, Inc. (the “Company”) and ModernaTX, Inc. (together with the Company, “Moderna”) and Arbut... | 8-K1.01 | 2026-03-05 |
| Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Upd...Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates | 8-K2.02 | 2026-02-13 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.